Related Experiment Video
Updated: Apr 21, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Management of asymptomatic myeloma patients
1Hospital Universitario de Salamanca - Hematology, Paseo San Vicente, 58-182 Salamanca, Spain.
Abstract:
Smoldering multiple myeloma is an asymptomatic disorder characterized by the presence of ≥30 g/l serum M-protein and/or ≥10% bone marrow plasma cell infiltration. The risk of progression to active multiple myeloma is not uniform, and several markers are useful for identifying patients at high risk of this. Although the current standard of care is not to treat, a randomized trial in high-risk smoldering multiple myeloma patients comparing those allocated to receive early treatment with lenalidomide plus dexamethasone with those under observation reported a significant benefit with respect to time to progression and overall survival. We conclude that efforts should be made to identify high-risk patients who are candidates for receiving early treatment before they develop myeloma-related symptomatology.
Insights
Early treatment with lenalidomide plus dexamethasone significantly benefits patients with high-risk smoldering multiple myeloma, improving time to progression and survival. Identifying these patients is crucial for proactive intervention before active disease develops.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Smoldering multiple myeloma (SMM) is defined by specific M-protein levels or bone marrow plasma cell infiltration.
- Progression risk in SMM varies, necessitating identification of high-risk individuals.
- Current standard care for SMM is observation, not active treatment.
Purpose of the Study:
- To evaluate the efficacy of early treatment versus observation in high-risk smoldering multiple myeloma patients.
- To assess the impact of lenalidomide plus dexamethasone on time to progression and overall survival in SMM.
Main Methods:
- A randomized clinical trial was conducted.
- High-risk smoldering multiple myeloma patients were allocated to either early treatment (lenalidomide plus dexamethasone) or observation.
- Outcomes measured included time to progression and overall survival.
Main Results:
- Early treatment with lenalidomide plus dexamethasone demonstrated a significant benefit.
- Patients receiving early treatment showed improved time to progression compared to observation.
- Overall survival was also significantly improved in the early treatment arm.
Conclusions:
- Early intervention with lenalidomide plus dexamethasone is beneficial for high-risk smoldering multiple myeloma.
- Identifying high-risk SMM patients for early treatment is recommended.
- Proactive treatment may prevent the development of myeloma-related symptomatology.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:22Myocarditis IV: Nursing Management
01:22Myasthenia Gravis ll: Pathophysiology
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:29Cardiomyopathy V: Interprofessional Care